TBC

This symposium addresses the critical shift toward multi-resolution, multi-modal approaches that enable the precise deconstruction of the tumor ecosystem to achieve a system-level understanding of cancer progression. The session will begin with an overview of emerging innovations expanding the resolution and scope of cancer research, followed by expert‑led research demonstrating the utility of spatial transcriptomics for tumor microenvironment analysis and high‑plex functional proteomics for uncovering protein‑level drivers of cancer biology. Building on these applications and using Illumina Connected Multiomics (ICM) as a framework, an R&D‑led technical deep dive will examine analytical considerations for single‑omic and integrated multiomic analysis across single‑cell, spatial, transcriptomic, proteomic, genomic, and epigenomic data. Through practical examples, this session will demonstrate how AI guided workflows, structured data exploration, and intuitive visualisation make advanced multiomic analysis accessible, enabling researchers to confidently apply multiomic approaches in their own studies. Join us to explore how these multidimensional results, powered by high‑fidelity sequencing and accessible data analytics are providing the clarity needed to decipher the functional drivers of cancer and advance the next wave of precision oncology.

Dr. Wiesner will highlight how Advanced Cell Diagnostics and Lunaphore, Bio-Techne brands, are transforming the future of oncology research and precision medicine with spatial biology tools. Dr. Karen, from the Weizmann Institute of Science, will talk about how modern lung cancer treatment depends on multiple biomarkers, but current diagnostic workflows exhaust small biopsies and slow down life-saving therapy decisions. Her team developed a multiplexed imaging approach that reads dozens of markers from one tissue section, enabling comprehensive diagnosis while conserving tissue and shortening turnaround time.